<DOC>
	<DOC>NCT01321567</DOC>
	<brief_summary>To investigate the efficacy and safety of PARIET twice daily (b.i.d.) in patients with Proton Pump Inhibitor-resistant reflux esophagitis</brief_summary>
	<brief_title>Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Esophagitis, Peptic</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>Inclusion criteria; Proton pump inhibitorresistant reflux esophagitis. (Patients who have mucosal breaks (erosions, ulcers) on endoscopy) Exclusion criteria; Patients with a history of hypersensitivity to any ingredients of PARIET. Patients on atazanavir sulfate.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>rabeprazole sodium</keyword>
	<keyword>refractory reflux esophagitis</keyword>
</DOC>